Welcome to our dedicated page for Immunovant news (Ticker: IMVT), a resource for investors and traders seeking the latest updates and insights on Immunovant stock.
Immunovant, Inc. reports recurring developments from a clinical-stage immunology business focused on anti-FcRn therapies for autoimmune diseases. Its news flow centers on IMVT-1402, a potential neonatal Fc receptor inhibitor, and batoclimab, with updates across Graves’ disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, difficult-to-treat rheumatoid arthritis, Sjögren’s disease, cutaneous lupus erythematosus and thyroid eye disease.
Company updates also cover quarterly operating results, research and development spending, trial design and clinical-study results, safety observations, cash runway, financing activity and shareholder voting matters. Because Immunovant operates in a single research, development and manufacturing segment, recurring disclosures are closely tied to clinical execution, product-candidate manufacturing and capital resources for autoimmune disease programs.
Immunovant, Inc. (Nasdaq: IMVT), a biopharmaceutical company specializing in autoimmune diseases, announced participation by CEO Pete Salzmann, M.D. in a fireside chat at Roivant R&D Day 2021 on September 28, 2021, at 4:00 p.m. ET. The event will be accessible via a live webcast, with a replay available for 30 days afterwards on the company's investor page. Immunovant is advancing IMVT-1401, an innovative treatment targeting diseases caused by harmful IgG antibodies.
Immunovant appoints Renee Barnett as Chief Financial Officer effective October 4, 2021, enhancing its executive leadership team. Ms. Barnett brings over 20 years of financial expertise in healthcare, having worked at Eli Lilly and most recently at AbleTo, Inc. Her appointment comes as Immunovant prepares to initiate pivotal trials for batoclimab (IMVT-1401) in multiple indications, including myasthenia gravis, and reinitiate programs for thyroid eye disease and warm autoimmune hemolytic anemia.
Immunovant (Nasdaq: IMVT) reported financial results for its fiscal first quarter ending June 30, 2021, highlighting approximately $379 million in cash and a $200 million strategic investment from Roivant. The FDA granted Orphan Drug Designation for IMVT-1401 to treat Myasthenia Gravis. R&D expenses increased to $18.7 million, while G&A expenses rose to $11.2 million. The net loss for the quarter was $30.5 million or $0.31 per share, compared to a net loss of $26.7 million or $0.38 per share in the previous year.
Immunovant, Inc. (Nasdaq: IMVT) will host a conference call and audio webcast on August 9, 2021, at 8 a.m. ET, to discuss its financial results for the first fiscal quarter ended June 30, 2021. Following prepared remarks, there will be a live Q&A session for investors. Immunovant is focused on developing IMVT-1401, a fully human anti-FcRn monoclonal antibody aimed at treating autoimmune diseases associated with pathogenic IgG antibodies.
On August 2, 2021, Immunovant announced a strategic investment of $200 million from Roivant Sciences. This investment will support the development of IMVT-1401 across multiple indications, enhancing Immunovant's financial position with a post-investment cash balance of approximately $600 million. Roivant acquired 17,021,276 shares at $11.75 each, increasing its ownership from 57.5% to 63.8%. Immunovant plans to initiate pivotal trials for myasthenia gravis and resume trials in WAIHA and TED over the next 12 months.
Immunovant (Nasdaq: IMVT) announced plans to resume clinical development of IMVT-1401 in Myasthenia Gravis (MG) and Warm Autoimmune Hemolytic Anemia (WAIHA). The company reported a cash balance of approximately $400 million as of March 31, 2021, and net losses increased to $107.4 million for the fiscal year, up from $66.4 million in 2020. A data review indicated that IMVT-1401 has a broader therapeutic window than expected, with manageable lipid elevations. The company intends to initiate multiple clinical studies over the next year as part of its developmental strategy.
Immunovant (Nasdaq: IMVT) reported its financial results for the third quarter and nine months ended December 31, 2020. The company ended the quarter with approximately $422 million in cash. However, it voluntarily paused dosing in its clinical trials for IMVT-1401 due to elevated cholesterol levels in patients. R&D expenses rose to $21.1 million, up from $5.0 million a year earlier, while net loss for the quarter was $31.8 million ($0.32 per share), compared to $11.3 million last year. Ongoing reviews and future updates are expected in Q2 2021.
Immunovant (Nasdaq: IMVT) has appointed Dr. Rita Jain as Chief Medical Officer, bringing over 20 years of drug development expertise. Dr. Jain's extensive experience in clinical trials, particularly in immunology and inflammation, positions her to lead multiple Phase 3 programs for IMVT-1401. Additionally, due to COVID-19-related site closures, results for key trials of IMVT-1401 are now delayed, with expectations for updates in Q2 and Q3 of 2021. The company remains optimistic about IMVT-1401's potential in various therapeutic areas.
Immunovant reported its fiscal second quarter results ending September 30, 2020, with approximately $444 million in cash and a net loss of $20.8 million ($0.25 per share). R&D expenses rose to $12.0 million primarily due to increased clinical trial costs. The company appointed Michael Elliott as Chief Scientific Officer and reported positive results from its IMVT-1401 trial for Myasthenia Gravis. Additionally, they raised $188 million through a public equity offering. Upcoming results for ongoing trials are anticipated in 2021.
Immunovant, Inc. (Nasdaq: IMVT) has successfully closed its underwritten public offering of 6,060,606 shares of common stock at $33.00 per share, raising approximately $200.0 million in gross proceeds. This includes the full exercise of an underwriters’ option for an additional 790,513 shares. The offering was managed by SVB Leerink, Guggenheim Securities, and Chardan, with LifeSci Capital and Baird as co-lead managers. The registration statements for these securities became effective on September 1, 2020.